IL250607B - תכשירי פרו–תרופה אריפיפראזול, ושימושים בהם - Google Patents

תכשירי פרו–תרופה אריפיפראזול, ושימושים בהם

Info

Publication number
IL250607B
IL250607B IL250607A IL25060717A IL250607B IL 250607 B IL250607 B IL 250607B IL 250607 A IL250607 A IL 250607A IL 25060717 A IL25060717 A IL 25060717A IL 250607 B IL250607 B IL 250607B
Authority
IL
Israel
Prior art keywords
aripiprazole prodrug
prodrug compositions
compositions
aripiprazole
prodrug
Prior art date
Application number
IL250607A
Other languages
English (en)
Other versions
IL250607A0 (he
Original Assignee
Alkermes Pharma Ireland Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51352472&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL250607(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Alkermes Pharma Ireland Ltd filed Critical Alkermes Pharma Ireland Ltd
Publication of IL250607A0 publication Critical patent/IL250607A0/he
Publication of IL250607B publication Critical patent/IL250607B/he

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL250607A 2014-08-18 2017-02-14 תכשירי פרו–תרופה אריפיפראזול, ושימושים בהם IL250607B (he)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462038665P 2014-08-18 2014-08-18
EP14181328 2014-08-18
PCT/EP2015/068872 WO2016026822A1 (en) 2014-08-18 2015-08-17 Aripiprazole prodrug compositions

Publications (2)

Publication Number Publication Date
IL250607A0 IL250607A0 (he) 2017-04-30
IL250607B true IL250607B (he) 2022-05-01

Family

ID=51352472

Family Applications (2)

Application Number Title Priority Date Filing Date
IL292079A IL292079B2 (he) 2014-08-18 2015-08-17 תכשירי פרותרופה אריפיפראזול, ושימושים בהם
IL250607A IL250607B (he) 2014-08-18 2017-02-14 תכשירי פרו–תרופה אריפיפראזול, ושימושים בהם

Family Applications Before (1)

Application Number Title Priority Date Filing Date
IL292079A IL292079B2 (he) 2014-08-18 2015-08-17 תכשירי פרותרופה אריפיפראזול, ושימושים בהם

Country Status (20)

Country Link
US (1) US20220079939A1 (he)
EP (2) EP3182958B2 (he)
JP (1) JP6571166B2 (he)
CN (3) CN106794251B (he)
AU (1) AU2015306198B2 (he)
BR (1) BR112017002926A2 (he)
CY (1) CY1124625T1 (he)
DK (1) DK3508196T3 (he)
ES (1) ES2884849T3 (he)
HR (1) HRP20211271T1 (he)
HU (1) HUE055711T2 (he)
IL (2) IL292079B2 (he)
MX (1) MX371417B (he)
PL (2) PL3508196T3 (he)
PT (1) PT3508196T (he)
RS (2) RS62232B1 (he)
RU (1) RU2705376C2 (he)
SI (2) SI3508196T1 (he)
SM (2) SMT201900236T1 (he)
WO (1) WO2016026822A1 (he)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10016415B2 (en) 2014-08-18 2018-07-10 Alkermes Pharma Ireland Limited Aripiprazole prodrug compositions
LT3508196T (lt) * 2014-08-18 2021-09-10 Alkermes Pharma Ireland Limited Aripiprazolo provaisto kompozicijos
WO2017143017A1 (en) * 2016-02-17 2017-08-24 Alkermes Pharma Ireland Limited Compositions of multiple aripiprazole prodrugs
CN110025572A (zh) * 2018-01-11 2019-07-19 四川科伦药物研究院有限公司 月桂酰阿立哌唑混悬剂及其制备方法
CA3092335A1 (en) * 2018-03-05 2019-09-12 Alkermes Pharma Ireland Limited Aripiprazole dosing strategy
CN110327296B (zh) * 2019-08-06 2021-10-22 深圳市泛谷药业股份有限公司 一种阿立哌唑长效注射制剂及其制备方法
KR20240018523A (ko) 2021-06-08 2024-02-13 추가이 세이야쿠 가부시키가이샤 다이하이드로피리다진-3,5-다이온 유도체를 함유하는 제제

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5145684A (en) * 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
AU660852B2 (en) 1992-11-25 1995-07-06 Elan Pharma International Limited Method of grinding pharmaceutical substances
US5336507A (en) 1992-12-11 1994-08-09 Sterling Winthrop Inc. Use of charged phospholipids to reduce nanoparticle aggregation
TW384224B (en) 1994-05-25 2000-03-11 Nano Sys Llc Method of preparing submicron particles of a therapeutic or diagnostic agent
US5718388A (en) 1994-05-25 1998-02-17 Eastman Kodak Continuous method of grinding pharmaceutical substances
US5662883A (en) 1995-01-10 1997-09-02 Nanosystems L.L.C. Microprecipitation of micro-nanoparticulate pharmaceutical agents
US5560932A (en) 1995-01-10 1996-10-01 Nano Systems L.L.C. Microprecipitation of nanoparticulate pharmaceutical agents
US5665331A (en) 1995-01-10 1997-09-09 Nanosystems L.L.C. Co-microprecipitation of nanoparticulate pharmaceutical agents with crystal growth modifiers
US5534270A (en) 1995-02-09 1996-07-09 Nanosystems Llc Method of preparing stable drug nanoparticles
US5510118A (en) 1995-02-14 1996-04-23 Nanosystems Llc Process for preparing therapeutic compositions containing nanoparticles
US5543133A (en) 1995-02-14 1996-08-06 Nanosystems L.L.C. Process of preparing x-ray contrast compositions containing nanoparticles
ATE386506T1 (de) 1995-10-17 2008-03-15 Jagotec Ag Verabreichung unlöslicher arzneistoffe
GB9622173D0 (en) 1996-10-24 1996-12-18 Glaxo Group Ltd Particulate Products
AU2002334939A1 (en) * 2001-10-12 2003-04-22 Eugene R. Cooper Compositions having a combination of particles for immediate release and for controlled release
US20050032811A1 (en) * 2003-08-06 2005-02-10 Josiah Brown Methods for administering aripiprazole
MXPA06004489A (es) * 2003-10-23 2006-06-20 Otsuka Pharma Co Ltd Formulacion y metodo de aripiprazol inyectable esteril de liberacion controlada.
CA2622758A1 (en) * 2005-09-15 2007-03-29 Elan Pharma International, Limited Nanoparticulate aripiprazole formulations
HUE033442T2 (en) 2009-06-25 2017-11-28 Alkermes Pharma Ireland Ltd Heterocyclic compounds for the treatment of neurological and psychological disorders
EP3156056B1 (en) * 2011-03-18 2023-12-06 Alkermes Pharma Ireland Limited Pharmaceutical compositions comprising sorbitan esters
AU2013235526B2 (en) * 2012-03-19 2017-11-30 Alkermes Pharma Ireland Limited Pharmaceutical compositions comprising benzyl alcohol
CA2867121C (en) * 2012-03-19 2021-05-25 Alkermes Pharma Ireland Limited Pharmaceutical compositions comprising fatty acid esters
ES2792149T3 (es) * 2012-09-19 2020-11-10 Alkermes Pharma Ireland Ltd Composiciones farmacéuticas que tienen estabilidad de almacenamiento mejorada

Also Published As

Publication number Publication date
SMT202100481T1 (it) 2021-09-14
PL3182958T3 (pl) 2019-07-31
WO2016026822A1 (en) 2016-02-25
PT3508196T (pt) 2021-08-25
IL250607A0 (he) 2017-04-30
US20220079939A1 (en) 2022-03-17
PL3182958T5 (pl) 2022-09-12
RS58746B1 (sr) 2019-06-28
JP6571166B2 (ja) 2019-09-04
CY1124625T1 (el) 2022-07-22
AU2015306198B2 (en) 2021-02-25
CN106794251B (zh) 2020-12-29
SMT201900236T1 (it) 2019-07-11
RU2017108204A (ru) 2018-09-21
CN112641785A (zh) 2021-04-13
RS62232B1 (sr) 2021-09-30
PL3508196T3 (pl) 2021-12-20
SI3508196T1 (sl) 2021-12-31
EP3508196A1 (en) 2019-07-10
HUE055711T2 (hu) 2021-12-28
SI3182958T2 (sl) 2022-07-29
EP3508196B1 (en) 2021-07-14
CA2957762A1 (en) 2016-02-25
JP2017524021A (ja) 2017-08-24
CN106794251A (zh) 2017-05-31
RS58746B2 (sr) 2022-07-29
CN112494492A (zh) 2021-03-16
NZ767204A (en) 2024-02-23
IL292079A (he) 2022-06-01
BR112017002926A2 (pt) 2017-12-12
DK3508196T3 (da) 2021-08-16
RU2705376C2 (ru) 2019-11-07
ES2884849T3 (es) 2021-12-13
NZ728914A (en) 2023-11-24
SI3182958T1 (sl) 2019-05-31
AU2015306198A1 (en) 2017-03-02
MX371417B (es) 2020-01-29
EP3182958B1 (en) 2019-02-27
EP3182958A1 (en) 2017-06-28
EP3182958B2 (en) 2022-05-18
HRP20211271T1 (hr) 2022-01-07
IL292079B1 (he) 2024-03-01
RU2017108204A3 (he) 2019-04-04
CN112494492B (zh) 2023-08-25
IL292079B2 (he) 2024-07-01
MX2017002029A (es) 2017-08-14

Similar Documents

Publication Publication Date Title
IL250568A0 (he) תכשירים אנטי-מתאנוגניים ושימושים בהם
ZA201701286B (en) Flagellin compositions and uses
ZA201605300B (en) Pharmaceutical compositions comprising azd9291
GB201412706D0 (en) Improved binder compositions and uses thereof
GB201618482D0 (en) Pharmaceutical compositions
GB201419257D0 (en) Pharmaceutical compositions
IL249553A0 (he) תכשירים רוקחיים
PL3134185T3 (pl) Kompozycje ochrony przeciwsłonecznej
IL250607B (he) תכשירי פרו–תרופה אריפיפראזול, ושימושים בהם
GB201408167D0 (en) Compositions
IL251479A0 (he) תרכיבים
IL250817A0 (he) תכשירי רוקחות
PT3200772T (pt) Composições farmacêuticas compreendendo alpelisib
GB201420306D0 (en) Compositions
HUE043169T2 (hu) Aripiprazol prodrug készítmények
GB201522814D0 (en) Compositions and uses thereof
GB201406863D0 (en) Compositions comprising variegin
GB201419849D0 (en) Compositions
SG2014014872A (en) Pharmaceutical compositions
GB201408432D0 (en) Pharmaceutical compositions
GB201413538D0 (en) Ophthalmic compositions and uses thereof